ArticleDiscover oncology2025
Dexamethasone, celecoxib, and simvastatin-induced 5-fluorouracil resistance in cancer cells: a possible role of lipid droplet accumulation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimThis study investigates the impact of dexamethasone (DEX), celecoxib (CXB), and simvastatin (SMV) on 5-fluorouracil (5-FU) resistance in cancer cells and their role in increasing lipid droplet (LD) accumulation. The study aims to assess how these non-anticancer drugs may influence the efficacy of 5-FU treatment, with potential implications for clinical outcomes.
methodsEight human cancer cell lines were treated with 5-FU alone and in combination with DEX, CXB, or SMV. LD levels were quantified using Oil Red O (ORO) staining, and cell viability was assessed with the sulforhodamine B (SRB) assay. Changes in LD levels and IC
resultsCo-treatment of 5-FU with DEX, CXB, and SMV significantly increased LD accumulation across the tested cancer cell lines and induced resistance to 5-FU. The impact varied between cell lines, with some showing marked reductions in 5-FU efficacy when combined with these drugs. The observed increase in LDs may contribute to the reduced therapeutic effects of 5-FU, potentially compromising its clinical effectiveness.
conclusionThe findings highlight that DEX, CXB, and SMV enhance 5-FU resistance by increasing LD accumulation, highlighting a critical, previously overlooked metabolic factor that may impact clinical treatment strategies and patient outcomes. If similar effects occur in clinical settings, the use of these drugs may need to be adjusted to avoid compromising cancer treatment efficacy. Further studies are warranted to evaluate this interaction and its implications in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.